Autologous Stem Cell Therapy in Stroke
Primary Purpose
Stroke
Status
Withdrawn
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Stem cell
Sponsored by

About this trial
This is an interventional treatment trial for Stroke focused on measuring Chronic Stroke, Subacute stroke, Autologous Bone Marrow Mononuclear Cell therapy, Stem cell
Eligibility Criteria
Inclusion Criteria:
- Age18 years-80 years
- diagnosed as stroke by clinical and MRI findings
Exclusion Criteria:
- presence of respiratory distress
- presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/ Hepatitis C Virus
- malignancies
- acute medical conditions such as respiratory infection, fever
- hemoglobin less than 8
- bleeding tendency
- bone marrow disorder
- left ventricular ejection fraction < 30%
- pregnancy or breastfeeding
Sites / Locations
- Neurogen brain and spine institute
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Stem Cell
Arm Description
Bone marrow mononuclear cells
Outcomes
Primary Outcome Measures
Functional Independence Measure
Functional Independence Measure scale assesses the patients ability to carry out activities of daily living. At the follow up of 1 year, every patient in this study will be reevaluated on this scale.
Secondary Outcome Measures
Full Information
NCT ID
NCT02245698
First Posted
September 12, 2014
Last Updated
October 23, 2018
Sponsor
Neurogen Brain and Spine Institute
1. Study Identification
Unique Protocol Identification Number
NCT02245698
Brief Title
Autologous Stem Cell Therapy in Stroke
Official Title
Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Stroke
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Withdrawn
Study Start Date
December 2008 (undefined)
Primary Completion Date
June 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neurogen Brain and Spine Institute
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with sub acute/chronic stroke.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
Chronic Stroke, Subacute stroke, Autologous Bone Marrow Mononuclear Cell therapy, Stem cell
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stem Cell
Arm Type
Experimental
Arm Description
Bone marrow mononuclear cells
Intervention Type
Biological
Intervention Name(s)
Stem cell
Intervention Description
Intrathecal autologous bone marrow mononuclear cell transplantation
Primary Outcome Measure Information:
Title
Functional Independence Measure
Description
Functional Independence Measure scale assesses the patients ability to carry out activities of daily living. At the follow up of 1 year, every patient in this study will be reevaluated on this scale.
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age18 years-80 years
diagnosed as stroke by clinical and MRI findings
Exclusion Criteria:
presence of respiratory distress
presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/ Hepatitis C Virus
malignancies
acute medical conditions such as respiratory infection, fever
hemoglobin less than 8
bleeding tendency
bone marrow disorder
left ventricular ejection fraction < 30%
pregnancy or breastfeeding
Facility Information:
Facility Name
Neurogen brain and spine institute
City
Navi Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400706
Country
India
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Autologous Stem Cell Therapy in Stroke
We'll reach out to this number within 24 hrs